XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Pre-funded warrants
Common Stock
Pre-funded warrants
Additional Paid-In Capital
Pre-funded warrants
Preferred Stock
Series E-2 Preferred Stock
Preferred Stock
Series E-3 preferred stock
Preferred Stock
Series E-4 preferred stock
Preferred Stock
Common Stock
Series E-2 Preferred Stock
Common Stock
Series E-3 preferred stock
Common Stock
Series E-4 preferred stock
Common Stock
Additional Paid-In Capital
Series E-2 Preferred Stock
Additional Paid-In Capital
Series E-3 preferred stock
Additional Paid-In Capital
Series E-4 preferred stock
Additional Paid-In Capital
Accumulated Deficit
Series E-4 preferred stock
Series D preferred stock
Total
Balance beginning at Dec. 31, 2023             $ 4,677,632       $ 7       $ 182,924,410 $ (202,761,017)     $ (15,158,968)
Balance beginning (in shares) at Dec. 31, 2023             319.76       691,470                
Increase (Decrease) in Stockholders' Equity (Deficit)                                      
Stock-based compensation                             4,272,780       4,272,780
Issuance of preferred stock, net of issuance costs           $ 15,914,632                     $ 15,914,632    
Issuance of preferred stock, net of issuance costs (in shares)           1,610                          
Conversion of preferred stock into common stock       $ (4,156,854) $ (47,577,000) $ (15,914,632)   $ 1 $ 5 $ 2   $ 4,156,853 $ 47,576,995 $ 15,914,630          
Conversion of preferred stock into common stock (in shares)       (284) (2,205) (1,610)   104,088 461,538 224,664                  
Exercise of warrants for preferred stock, net of issuance costs (Note 2)             $ 47,577,000                       47,577,000
Exercise of warrants for preferred stock, net of issuance costs (Note 2) (in shares)             2,205                        
Exercise of warrants for common stock, net of issuance costs   $ 3,972,540 $ 3,972,540                       2,298,143       $ 2,298,143
Exercise of warrants for common stock, net of issuance costs (in shares) 35,971                   18,239                
Stock option exercise into common stock (in shares)                     26               55
Net loss                               (44,581,446)     $ (44,581,446)
Balance ending at Dec. 31, 2024             $ 520,778       $ 15       261,116,351 (247,342,463)     14,294,681
Balance ending (in shares) at Dec. 31, 2024             35.6       1,535,996                
Balance beginning Series D preferred stock at Dec. 31, 2023                                   $ 1,382,023  
Balance beginning Series D preferred stock (in shares) at Dec. 31, 2023                                   111.11  
Balance ending Series D preferred stock at Dec. 31, 2024                                   $ 1,382,023  
Balance ending Series D preferred stock (in shares) at Dec. 31, 2024                                   111.11  
Increase (Decrease) in Stockholders' Equity (Deficit)                                      
Stock-based compensation                             2,263,703       2,263,703
Issuance of preferred stock, net of issuance costs             $ 0       $ 11       5,788,369 0   $ 0 5,788,380
Issuance of preferred stock, net of issuance costs (in shares)                     1,045,000                
Exercise of warrants for common stock, net of issuance costs             0       $ 16       7,981,421       7,981,437
Exercise of warrants for common stock, net of issuance costs (in shares)                     1,659,138                
Retired shares (in shares)                     (5)                
Net loss                               (21,791,037)     (21,791,037)
Balance ending at Dec. 31, 2025             $ 520,778       $ 42       $ 277,149,844 $ (269,133,500)     $ 8,537,164
Balance ending (in shares) at Dec. 31, 2025             35.6       4,240,129                
Balance ending Series D preferred stock at Dec. 31, 2025                                   $ 1,382,023  
Balance ending Series D preferred stock (in shares) at Dec. 31, 2025                                   111.11